Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappointing trial results.The new data comes from the phase 2/3 SKYSCRAPER-06 study, which evaluated tiragolumab in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) and chemotherapy as a first-line treatment for locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).The regimen was compared to MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and chemo in the trial, and showed reduced efficacy compared to the control arm, according to a Roche statement released this morning.Progression-free survival (PFS as well as overall survival was worse in the tiragolumab arm, which Roche’s chief medical officer Levi Garraway said was a “disappointing” result but would “inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.”Roche has another half-dozen phase 3 trials on the go with tiragolumab in other NSCLC settings, oesophageal cancer, and liver cancer.

罗氏公司的抗TIGIT药物tiragolumab未能通过一项肺癌研究，削弱了人们对该项目的热情，因为有迹象表明，在一系列令人失望的试验结果之后，该项目正在恢复正常。新数据来自2/3期摩天大楼-06研究，该研究评估了替拉鲁单抗联合罗氏PD-L1抑制剂Tecentriq（atezolizumab）和化疗作为局部晚期不可切除或转移性非鳞状非小细胞肺癌（NSCLC）的一线治疗。根据罗氏今晨发布的一份声明，该方案与MSD的PD-1抑制剂Keytruda（pembrolizumab）和chemo在试验中进行了比较，与对照组相比，疗效降低。罗氏首席医疗官Levi Garraway表示，替拉格单抗组的无进展生存期（PFS）和总生存期较差，这是一个“令人失望”的结果，但将“告知我们对抗TIGIT途径和癌症研究新途径的科学理解。”罗氏在其他NSCLC环境，食道癌和肝癌中与替拉格单抗进行了另外六项3期临床试验。

It has been hoping to start filing for approval of the drug in 2025.In 2022, Roche reported that tiragolumab missed the mark in a pair of phase 3 lung cancer studies – SKYSCRAPER-1 in NSCLC and SKYSCRAPER-2 in extensive-stage small-cell lung cancer (ES-SCLC) – raising doubts about the future of the drug.SKYSCRAPER-1 missed the PFS endpoint but patients continued to be followed to the OS readout and, last year, there was a surprise revelation that OS in the tiragolumab/Tecentriq group was trending towards an improvement over Tecentriq alone.Roche meanwhile also reported positive results in a phase 1b/2 trial in liver cancer at last year’s ASCO congress, restor.

罗氏一直希望在2025年开始申请该药物的批准。2022年，罗氏报告说，在一对3期肺癌研究中，tiragolumab没有达到目标-NSCLC中的摩天大楼-1和广泛期小细胞肺癌（ES-SCLC）中的摩天大楼-2-引起了人们对该药物未来的怀疑。摩天大楼-1错过了PFS终点，但患者继续接受OS读数，去年，令人惊讶的是，tiragolumab/Tecentriq组的OS比单独使用Tecentriq有改善的趋势。与此同时，罗氏在去年的ASCO大会restor上也报告了肝癌1b/2期试验的阳性结果。